Sean MacDonald
Director/Board Member chez EDESA BIOTECH, INC.
Fortune : 8 606 $ au 31/03/2024
Profil
Sean A.
MacDonald is currently the Chief Executive Officer at Domain Therapeutics SA. He is also the Director of Sales & Licensing at Bioneer A.
Additionally, he serves as an Independent Director at Edesa Biotech, Inc. Previously, Mr. MacDonald held the position of Chief Executive Officer at Corbin Therapeutics, Inc. from 2018 to 2021.
He was also the Director of Business Development at Ablynx NV.
Mr. MacDonald served as a Director at Edesa Biotech, Inc. (Old) and Edesa Biotech Research, Inc. from 2017 to 2019.
He held the role of Vice President of Business Development at Pharmascience, Inc. from 2012 to 2018.
Furthermore, he was the Head of Business Development at Cosmo Pharmaceuticals NV from 2019 to 2021.
Mr. MacDonald briefly served as the Chief Business Officer at iOnctura SA in 2021.
Mr. MacDonald obtained his undergraduate degree and an MBA from the University of Ottawa.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
EDESA BIOTECH, INC.
0,06% | 02/04/2024 | 2 053 ( 0,06% ) | 8 606 $ | 31/03/2024 |
Postes actifs de Sean MacDonald
| Sociétés | Poste | Début |
|---|---|---|
| EDESA BIOTECH, INC. | Director/Board Member | 01/05/2023 |
Bioneer A/S
 Bioneer A/S Pharmaceuticals: MajorHealth Technology Bioneer A/S develops and manufactures drugs. The firm's products and services drug development, molecular histology, dynamic gastric model, biomarkers and drug targets, protein manufacturing, mammalian cell technology, immune targeting, active ingredients and microorganisms. The company was founded in 2003 and is headquartered in Horsholm, Denmark. | Sales & Marketing | - |
Domain Therapeutics SA
 Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Chief Executive Officer | 17/04/2024 |
Anciens postes connus de Sean MacDonald
| Sociétés | Poste | Fin |
|---|---|---|
iOnctura SA
 iOnctura SA Miscellaneous Commercial ServicesCommercial Services iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland. | Corporate Officer/Principal | 01/04/2022 |
Corbin Therapeutics, Inc.
 Corbin Therapeutics, Inc. Internet Software/ServicesTechnology Services Corbin Therapeutics, Inc. operates as a biotechnology platform. | Chief Executive Officer | 01/08/2021 |
| COSMO PHARMACEUTICALS N.V. | Corporate Officer/Principal | 01/08/2021 |
| Edesa Biotech Research, Inc. | Director/Board Member | 01/06/2019 |
Pharmascience, Inc.
 Pharmascience, Inc. Pharmaceuticals: MajorHealth Technology Pharmascience, Inc. manufactures and distributes generic and drug products. It offers liquids, tablets, capsules, suppositories, powders, and ophthalmic. The company was founded by Morris Goodman and Ted S. Wise in 1983 and is headquartered in Montr?al, Canada. | Corporate Officer/Principal | 01/10/2018 |
Formation de Sean MacDonald
| University of Ottawa | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| COSMO PHARMACEUTICALS N.V. | Health Technology |
| Entreprise privées | 9 |
|---|---|
Ablynx NV
 Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
Bioneer A/S
Bioneer A/S Pharmaceuticals: MajorHealth Technology Bioneer A/S develops and manufactures drugs. The firm's products and services drug development, molecular histology, dynamic gastric model, biomarkers and drug targets, protein manufacturing, mammalian cell technology, immune targeting, active ingredients and microorganisms. The company was founded in 2003 and is headquartered in Horsholm, Denmark. | Health Technology |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Health Technology |
Pharmascience, Inc.
Pharmascience, Inc. Pharmaceuticals: MajorHealth Technology Pharmascience, Inc. manufactures and distributes generic and drug products. It offers liquids, tablets, capsules, suppositories, powders, and ophthalmic. The company was founded by Morris Goodman and Ted S. Wise in 1983 and is headquartered in Montr?al, Canada. | Health Technology |
iOnctura SA
iOnctura SA Miscellaneous Commercial ServicesCommercial Services iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland. | Commercial Services |
Edesa Biotech, Inc. (Old)
 Edesa Biotech, Inc. (Old) Pharmaceuticals: MajorHealth Technology Edesa Biotech, Inc. engages in the development of treatments for dermatological and anorectal diseases. Its product pipeline is based on non-steroidal molecules for the treatment of allergic contact dermatitis, hemorrhoids, and anal fissures. The company was founded by Par Nijhawan in 2015 and is headquartered in Markham, Canada. | Health Technology |
| Edesa Biotech, Inc. | |
Corbin Therapeutics, Inc.
Corbin Therapeutics, Inc. Internet Software/ServicesTechnology Services Corbin Therapeutics, Inc. operates as a biotechnology platform. | Technology Services |
| Edesa Biotech Research, Inc. |
